Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Matritech detects NMP in early stage breast cancer:

This article was originally published in Clinica

Executive Summary

The nuclear matrix protein NMP66 is present in the blood of women even at the earliest stages of breast cancer, a study by Matritech has revealed. The protein was found to be absent in the blood of normal women and in those with the benign breast disease fibroadenoma, therefore confirming the specificity of NMP66 to breast cancer at all stages of the disease, said the Newton, Massachusetts-based company. Matritech, whose NMP22 test kit for bladder cancer was cleared by the FDA in 1996, is currently developing a breast cancer test kit using NMP66 as a tumour marker.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT075549

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel